ATH-1105 a Phase 1, Double-Blind, Placebo-Controlled, Single-and-Multiple-Oral-Dose, Safety, Tolerability, and Pharmacokinetic Study in Healthy Male and Female Subjects
Latest Information Update: 19 May 2025
At a glance
- Drugs ATH 1105 (Primary)
- Indications Amyotrophic lateral sclerosis; Frontotemporal dementia
- Focus Adverse reactions; First in man
- Sponsors Athira Pharma
Most Recent Events
- 13 May 2025 Results presented in the Athira Pharma Media Release.
- 09 May 2025 According to an Athira Pharma media release, company will present data from this study at the 4th Annual ALS Drug Development Summit taking place May 12-14, 2025, in Boston, Massachusetts.
- 09 May 2025 According to an Athira Pharma media release, company look forward to sharing the full results from this study in the second half of 2025 and company is on-track to enable dosing ALS patients in late 2025.